Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

Brian Godman, Iain Bishop, Alexander Finlayson, Stephen Campbell, Hye-Young Kwon, Marion Bennie

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors’ found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin–angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any ‘spillover’ effects to affect future prescribing, even in closely related classes
Original languageEnglish
Pages (from-to)469-482
Number of pages14
JournalExpert Review of Pharmacoeconomics Outcomes Research
Volume13
Issue number4
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Generic Drugs
Scotland
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Risperidone
Losartan
Proton Pump Inhibitors
Angiotensin Receptor Antagonists
Serotonin Uptake Inhibitors
Health Expenditures
Antipsychotic Agents
Habits
Names
Prescriptions
Physicians
Costs and Cost Analysis
Pharmaceutical Preparations

Cite this

Godman, Brian ; Bishop, Iain ; Finlayson, Alexander ; Campbell, Stephen ; Kwon, Hye-Young ; Bennie, Marion. / Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. In: Expert Review of Pharmacoeconomics Outcomes Research. 2013 ; Vol. 13, No. 4. pp. 469-482.
@article{71c3b6e5e2b449568c0ea5011d33f2ea,
title = "Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries",
abstract = "Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors’ found supply-side measures resulted in generic prices as low as 3{\%} of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin–angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any ‘spillover’ effects to affect future prescribing, even in closely related classes",
author = "Brian Godman and Iain Bishop and Alexander Finlayson and Stephen Campbell and Hye-Young Kwon and Marion Bennie",
year = "2013",
doi = "10.1586/14737167.2013.820956",
language = "English",
volume = "13",
pages = "469--482",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. / Godman, Brian; Bishop, Iain; Finlayson, Alexander; Campbell, Stephen; Kwon, Hye-Young; Bennie, Marion.

In: Expert Review of Pharmacoeconomics Outcomes Research, Vol. 13, No. 4, 2013, p. 469-482.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

AU - Godman, Brian

AU - Bishop, Iain

AU - Finlayson, Alexander

AU - Campbell, Stephen

AU - Kwon, Hye-Young

AU - Bennie, Marion

PY - 2013

Y1 - 2013

N2 - Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors’ found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin–angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any ‘spillover’ effects to affect future prescribing, even in closely related classes

AB - Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors’ found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin–angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any ‘spillover’ effects to affect future prescribing, even in closely related classes

U2 - 10.1586/14737167.2013.820956

DO - 10.1586/14737167.2013.820956

M3 - Article

VL - 13

SP - 469

EP - 482

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 4

ER -